MedPath

Outcomes After Esophageal Cancer Surgery

Completed
Conditions
Esophageal Neoplasm
Esophageal Disease
Interventions
Procedure: Esophagectomy
Registration Number
NCT01927016
Lead Sponsor
University Hospital, Lille
Brief Summary

Background

* Esophageal carcinoma is the sixth leading cause of cancer -related mortality and the eighth most common cancer worldwide

* The incidence is increasing rapidly

* The overall 5-year survival ranges from 15% to 25% in the literature and poor outcomes are related to diagnosis at advanced stages.

* Surgery used to be the cornerstone of treatment of resectable esophageal cancer, but treatment of esophageal carcinoma remains challenging and need to be considered through a multimodal approach. However the modalities and the impact of this multimodal approach at a national level are unknown Primary objective: To identify predictors of recurrence after esophageal cancer surgery

Secondary objectives :

* 5-year recurrence free survival

* 5-year overall survival

* Predictors of postoperative mortality and morbidity after surgery

* Impact of pCR on recurrence and survival

* Impact of neoadjuvant treatments on recurrence and survival

* Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach...) on outcomes

Methodology : European French-speaking retrospective multicentric study Inclusion criteria: All consecutive patients operated on, for a histologically proven carcinoma of the esophagus, the oesophago-gastric junction (Siewert type I and II), in surgical investigator centers between January 2000 and December 2010 Exclusion criteria: Siewert III type carcinoma of the oesophago-gastric junction , non surgical treatment of esophageal carcinoma Planned study period: The data will be collected over a 11-year period from January 2000 to December 2010. Follow up will be ascertained in May 2013.

Detailed Description

Patients with an esophageal or junctional carcinoma (including SIewert type I and II) with surgical resection of the primary tumor inclusion date will be date of surgery all patients will be followed during 5 years after surgery or time of death

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2944
Inclusion Criteria
  • All consecutive patients operated on for a cancer of the esophagus , a Siewert I or II cancer of the esopgago-gastric junction in surgical oncology investigator centers
  • Surgery performed between 1st January 2000 and 31 December 2010
Exclusion Criteria
  • Siewert III cancer of the oesophago-gastric junction
  • Non surgical treatment of the esophageal cancer
  • Benign lesion

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Esophagectomy for cancerEsophagectomyPatients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
Primary Outcome Measures
NameTimeMethod
To identify predictors of recurrence after esophageal cancer surgery30 May 2012

clinical factors linked to 5-year recurrence will be identify through univariable and multivariable analysis

Secondary Outcome Measures
NameTimeMethod
Predictors of postoperative mortality and morbidity after surgery30 May 2012

30-day postoperative mortality and 30-day overall postoperative morbidity

5 year recurrence free survival30 May 2012

events: death and recurrence at 5 years after surgery

Impact of pCR on recurrence and survival30 May 2012

pathological complete response within the tumor and nodes

Impact of neoadjuvant treatments on recurrence and survival30 May 2012

looking at the impact of neoadjuvant chemo and/or chemoradiation on oncological outcomes

Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes30 May 2012

looking at the impact of nutritional support, endoscopic and surgical procedures on outcomes

5 year overall survival30 may 2012

all causes for death at 5 years after surgery

Trial Locations

Locations (1)

University Hospital, Lille

🇫🇷

Lille, France

© Copyright 2025. All Rights Reserved by MedPath